Direct-to-Consumer Blood Tests for Alzheimer’s Disease: Market Growth and Industry Considerations

Blood-based biomarker tests for Alzheimer’s disease, including the FDA-approved p-tau217 test, have become available since 2025 and are now offered by several direct-to-consumer (DTC) companies. These tests enable potentially earlier, more accessible, and less expensive screening compared to traditional methods like PET scans and spinal taps. However, experts caution that Alzheimer’s diagnosis remains complex and typically involves thorough cognitive evaluations alongside biomarker tests. Most DTC services combine biomarker testing with online cognitive assessments and offer consultations with wellness coaches or neurologists depending on test results. Pricing varies, with some companies offering bundled brain health packages that include lifestyle coaching aimed at dementia risk reduction. Despite the convenience and appeal of at-home testing, concerns remain regarding test accuracy, potential for false positives or negatives, and the psychological impact of receiving results outside a clinical setting. Clinicians emphasize the importance of integrating clinical history, cognitive function, and specialist consultation to confirm diagnoses and discuss implications. Additionally, the detection of amyloid plaques or biomarkers does not guarantee an individual will develop Alzheimer’s, adding complexity to result interpretation. Privacy and insurance discrimination issues related to biomarker data are also highlighted as areas requiring caution. While DTC Alzheimer’s testing could alleviate bottlenecks in dementia care and facilitate earlier treatment with emerging FDA-approved therapies, medical professionals recommend cautious consumer use and highlight the importance of supervised diagnostic processes.